Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
24 Octubre 2023 - 8:00AM
Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:
DRTS, DRTSW), the developer of the innovative alpha-radiation
cancer therapy Alpha DaRT™, announced today that Stephen M. Hahn,
M.D., former commissioner of the U.S. Food and Drug Administration
(“FDA”), has joined its Scientific Advisory Board. A distinguished
expert in the field of radiation oncology and
translational/clinical research, and a renowned physician, Dr. Hahn
brings a wealth of regulatory and scientific experience to the
Company as it advances its Alpha DaRT technology towards FDA
clearance.
“I am pleased to welcome Dr. Hahn to the Alpha Tau Scientific
Advisory Board at an ideal time in the Company’s growth
trajectory,” said Company CEO Uzi Sofer. “As we continue to focus
on executing our clinical strategy, including with our ongoing
multicenter ReSTART pivotal trial for recurrent Squamous Cell
Carcinoma of the skin, and on broadening the Alpha DaRT treatment
to other indications such as pancreatic, head and neck, and
prostate cancers and glioblastoma, which the Company is already
exploring in clinical trials in earnest, Dr. Hahn’s vast expertise
and insight will be of tremendous value. We are very excited by
what this wonderful partnership can potentially offer cancer
patients worldwide.”
Dr. Hahn is currently CEO-Partner of Flagship Pioneering and CEO
of Harbinger Health, where he specializes in innovating in the
field of preventive health care and global health strategy. He
previously served as FDA Commissioner from 2019 to 2021, overseeing
regulatory affairs, including therapeutics and vaccine development,
devices, diagnostics, and clinical trials. Prior to his FDA
appointment, Dr. Hahn served as chief medical executive, deputy
president, and chief operating officer at the world renowned MD
Anderson Cancer Center in Houston, Texas. Prior to his executive
leadership roles at MD Anderson, Dr. Hahn was at the helm of
radiation oncology at the University of Pennsylvania’s Perelman
School of Medicine.
“I have been watching Alpha Tau’s development with excitement
for quite some time,” said Dr. Hahn. “I am delighted to be joining
the Company and to help contribute towards introducing a new
modality for the treatment of cancer which will hopefully break new
ground in the field of radiation oncology, and which has very
promising potential as a combination with immunotherapy for
advanced metastatic patients.”
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company
that focuses on research, development, and potential
commercialization of the Alpha DaRT for the treatment of solid
tumors. The technology was initially developed by Prof. Itzhak
Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT™
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is
designed to enable highly potent and conformal alpha-irradiation of
solid tumors by intratumoral delivery of radium-224 impregnated
sources. When the radium decays, its short-lived daughters are
released from the sources and disperse while emitting high-energy
alpha particles with the goal of destroying the tumor. Since the
alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims
to mainly affect the tumor, and to spare the healthy tissue around
it.
Forward-Looking Statements
This press release includes "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. When used herein, words including "anticipate," "being,"
"will," "plan," "may," "continue," and similar expressions are
intended to identify forward-looking statements. In addition, any
statements or information that refer to expectations, beliefs,
plans, projections, objectives, performance or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking. All forward-looking
statements are based upon Alpha Tau's current expectations and
various assumptions. Alpha Tau believes there is a reasonable basis
for its expectations and beliefs, but they are inherently
uncertain. Alpha Tau may not realize its expectations, and its
beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking
statements as a result of various important factors, including,
without limitation: (i) Alpha Tau's ability to receive regulatory
approval for its Alpha DaRT technology or any future products or
product candidates; (ii) Alpha Tau's limited operating history;
(iii) Alpha Tau's incurrence of significant losses to date; (iv)
Alpha Tau's need for additional funding and ability to raise
capital when needed; (v) Alpha Tau's limited experience in medical
device discovery and development; (vi) Alpha Tau's dependence on
the success and commercialization of the Alpha DaRT technology;
(vii) the failure of preliminary data from Alpha Tau's clinical
studies to predict final study results; (viii) failure of Alpha
Tau's early clinical studies or preclinical studies to predict
future clinical studies; (ix) Alpha Tau's ability to enroll
patients in its clinical trials; (x) undesirable side effects
caused by Alpha Tau's Alpha DaRT technology or any future products
or product candidates; (xi) Alpha Tau's exposure to patent
infringement lawsuits; (xii) Alpha Tau's ability to comply with the
extensive regulations applicable to it; (xiii) the ability to meet
Nasdaq's listing standards; (xiv) costs related to being a public
company; (xv) changes in applicable laws or regulations; and the
other important factors discussed under the caption "Risk Factors"
in Alpha Tau's annual report filed on form 20-F with the SEC on
March 9, 2023, and other filings that Alpha Tau may make with the
United States Securities and Exchange Commission. These and other
important factors could cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent
management's estimates as of the date of this press release. While
Alpha Tau may elect to update such forward-looking statements at
some point in the future, except as required by law, it disclaims
any obligation to do so, even if subsequent events cause its views
to change. These forward-looking statements should not be relied
upon as representing Alpha Tau's views as of any date subsequent to
the date of this press release.
Investor Relations Contact
IR@alphatau.com
Alpha Tau Medical (NASDAQ:DRTSW)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Alpha Tau Medical (NASDAQ:DRTSW)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024